Tonix Pharmaceuticals Enters $150 Million Sales Agreement with A.G.P. and $75 Million Purchase Agreement with Lincoln Park

Reuters
12 Jun
Tonix Pharmaceuticals Enters $150 Million Sales Agreement with A.G.P. and $75 Million Purchase Agreement with Lincoln Park

Tonix Pharmaceuticals Holding Corp. has announced the entry into a Sales Agreement with A.G.P./Alliance Global Partners, allowing the company to offer and sell up to $150 million of its common stock through A.G.P. as a sales agent. The agreement does not obligate the company to sell any shares but permits sales to be made at the company's discretion, consistent with applicable laws and regulations. Additionally, Tonix has entered into a Purchase Agreement with Lincoln Park Capital Fund, LLC, enabling the sale of up to $75 million of newly issued shares of common stock. These agreements provide Tonix with the flexibility to raise capital as needed to support its operations and strategic initiatives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001999371-25-007625), on June 11, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10